论文部分内容阅读
血液病是严重威胁人们身心健康的难治性疾病。中国医科大学附属第二医院联络北京、天津、江苏、四川、浙江、湖南、湖北、宁夏、河南、黑龙江、辽宁等11个省、市自治区,21个临床医院及中国医学科学院血液病研究所,组成了氨肽素治疗血液病协作组。本组自1980年8月至1982年8月,对350例原发性血小板减少性紫癜以下简称(ITP)、慢性再生障碍性贫血,过敏性紫癜,及白细胞减少症进行临床疗效观察,现将结果汇总如下:
Blood disease is a refractory disease that seriously threatens people’s physical and mental health. The Second Affiliated Hospital of China Medical University contacted 11 provincial and municipalities and 21 clinical hospitals in Beijing, Tianjin, Jiangsu, Sichuan, Zhejiang, Hunan, Hubei, Ningxia, Henan, Heilongjiang and Liaoning and the Institute of Hematology, Chinese Academy of Medical Sciences, Composed of aminopeptin treatment of hematological disease team. The group from August 1980 to August 1982, 350 cases of idiopathic thrombocytopenic purpura (hereinafter referred to as ITP), chronic aplastic anemia, Henoch-Schonlein Purpura, and leukopenia clinical efficacy of observation, will now The results are summarized as follows: